Oncolytics Biotech^® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech® Inc. will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX with or without the PD-L1 immune checkpoint inhibitor atezolizumab in newly diagnosed patients with PDAC.